Form 8-K - Current report:
SEC Accession No. 0001628280-25-011839
Filing Date
2025-03-11
Accepted
2025-03-11 08:51:30
Documents
15
Period of Report
2025-03-10
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20250311.htm   iXBRL 8-K 30322
2 EX-99.1 ovid2024q4exhibit991.htm EX-99.1 82927
6 ovid-therapeutics_logo750sa.jpg GRAPHIC 23227
  Complete submission text file 0001628280-25-011839.txt   284147

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20250311.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20250311_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20250311_pre.xml EX-101.PRE 13044
18 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20250311_htm.xml XML 2720
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 25725982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)